论文部分内容阅读
目的探讨瑞替普酶静脉溶栓治疗急性心肌梗死的临床疗效。方法选取2013年3月—2015年6月山西中条山集团总医院收治的急性心肌梗死患者50例,随机分为试验组与对照组,各25例。对照组患者予以尿激酶原治疗,试验组患者予以瑞替普酶静脉溶栓治疗。观察两组患者溶栓再通情况、胸痛缓解(缓解、未缓解)情况及不良反应发生情况。结果试验组患者溶栓再通率、胸痛缓解率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论瑞替普酶静脉溶栓治疗急性心肌梗死的临床疗效显著,可缓解患者胸痛,且不良反应少。
Objective To investigate the clinical efficacy of reteplase intravenous thrombolysis in the treatment of acute myocardial infarction. Methods Fifty patients with acute myocardial infarction admitted from March 2013 to June 2015 in Zhongtiaoshan Group General Hospital of Shanxi were randomly divided into test group and control group, with 25 cases each. Patients in the control group were treated with urokinase and patients in the test group were treated with intravenous thrombolysis of reteplase. Thrombolytic recanalization, chest pain relief (remission, non-remission) and incidence of adverse reactions were observed in both groups. Results The rate of thrombolytic recanalization and chest pain in trial group was higher than that in control group, and the incidence of adverse reactions was lower than that in control group. The difference was statistically significant (P <0.05). Conclusion Reteplase intravenous thrombolysis in the treatment of acute myocardial infarction significant clinical effect, relieve chest pain in patients with less adverse reactions.